ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

This study has been completed.

Sponsored by: The Medicines Company
Information provided by: The Medicines Company
ClinicalTrials.gov Identifier: NCT00079586
  Purpose

The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.


Condition Intervention Phase
Cardiovascular Disease
Coronary Artery Bypass Surgery
Drug: Angiomax (bivalirudin)
Phase III

MedlinePlus related topics:   Blood Thinners    Coronary Artery Bypass Surgery   

Drug Information available for:   Heparin    Bivalirudin    Protamine   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)

Further study details as provided by The Medicines Company:

Estimated Enrollment:   150
Study Start Date:   April 2004

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

  • Provide written informed consent before initiation of any study related procedures.
  • Be at least 18 years of age.
  • Be scheduled for CABG, CABG and single valve surgery, or isolated single valve surgery on CPB. Patients undergoing repeat (redo) CABG are also considered eligible for this study.

Exclusion Criteria

  • Confirmed pregnancy at time of randomization via IVRS (if woman of child-bearing potential) (Urine or serum pregnancy test)
  • Cerebrovascular accident within 6 months, or any cerebrovascular accident with a residual neurological deficit.
  • Intracranial neoplasm, arteriovenous malformation or aneurysm.
  • Dependency on renal dialysis or creatinine clearance <30 mL/min.
  • Ongoing treatment with warfarin (or other oral anticoagulant) at the time of randomization.

Patients previously treated with warfarin may be enrolled if warfarin therapy can be safely discontinued and baseline INR is < 1.3 times control in the absence of heparin therapy.

  • Known allergy to Angiomax or hirudin-derived drugs, or known sensitivity to any component of the product.
  • Patients receiving clopidogrel (Plavix®) within the previous 5 days of randomization
  • Patients receiving a glycoprotein IIb/IIIa inhibitor within the previous 48 hours if abciximab (ReoPro®) or 24 hours if eptifibatide (Integrilin®) or tirofiban (Aggrastat®) of randomization.
  • Patients receiving lepirudin (Refludan®) or argatroban within the previous 24 hours prior to randomization.
  • Patients receiving LMWH or thrombolytics within the previous 12 hours or unfractionated heparin within 30 minutes of randomization.
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization.
  • Refusal to undergo blood transfusion should it become necessary.
  • Any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial.
  • Planned surgical procedure in which proximal anastomoses will precede distal anastomoses of the bypass grafts.
  • Planned (>1) double (or greater) valve repair-replacement (e.g.: AVR-MVR) surgery.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079586

Locations
United States, Ohio
The Cleveland Clinic    
      Cleveland, Ohio, United States, 44195

Sponsors and Collaborators
The Medicines Company

Investigators
Study Director:     Malcolm Lloyd, MD     The Medicines Company    
  More Information


Study ID Numbers:   TMC-BIV-02-06, EVOLUTION-On
First Received:   March 9, 2004
Last Updated:   March 16, 2006
ClinicalTrials.gov Identifier:   NCT00079586
Health Authority:   United States: Food and Drug Administration

Study placed in the following topic categories:
Bivalirudin
Protamines
Heparin
Calcium heparin

Additional relevant MeSH terms:
Anticoagulants
Therapeutic Uses
Hematologic Agents
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers